
**Roche: Bank of America/Merrill Lynch 2014
Health Care Conference, Las Vegas, 14 May**

*Thomas Kudsk Larsen, Head of Investor
Relations North America, Vice President*



Forward-looking statements

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1. pricing and product initiatives of competitors;
2. legislative and regulatory developments and economic conditions;
3. delay or inability in obtaining regulatory approvals or bringing products to market;
4. fluctuations in currency exchange rates and general financial market conditions;
5. uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
6. increased government pricing pressures;
7. interruptions in production;
8. loss of or inability to obtain adequate protection for intellectual property rights;
9. Litigation;
10. loss of key executives or other employees; and
11. adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com. All mentioned trademarks are legally protected.

Group: Q1 2014 highlights

Innovation

- EU: Subcutaneous formulation of MabThera approved
- US: Xolair approved in chronic idiopathic urticaria
- HPV test recommended for primary cervical cancer screening in US

Growth

- Strong growth in Pharma and Diagnostics
- HER2 franchise with recently launched Perjeta and Kadcyra continues good growth (+17%)
- Immunology and ophthalmology showing solid growth

Acquisition of IQuum


- Strengthen leading Molecular Diagnostics offering
- Rapid and simple testing at Point of Care , closer to patients

Group: Q1 2014 strong sales growth

	2014 CHFbn	2013 CHFbn	Change in %	
			CHF	CER
Pharmaceuticals Division	9.0	9.2	-1	4
Diagnostics Division	2.5	2.4	2	7
Roche Group	11.5	11.6	-1	5




Group: Q1 2014 both Divisions grew in all regions



All growth rates at constant exchange rates


Pharma: Q1 2014 highlights

Oncology & Actemra main growth drivers



Absolute amounts and growth rates at constant exchange rates (2013)

Pharma: HER2 franchise new standard of care



Kadcyla

- US: Increasing use in labeled indications
- EU: Successful ongoing launch
- Japan: Launch expected Q2 '14
- MARIANNE results expected H2 '14

Perjeta

- US: Strong adoption in neo-adjuvant setting; continued growth in 1L mBC
- Final CLEOPATRA OS data planned to be presented at ESMO (Sept '14)

Herceptin

- Herceptin SC launched in 18 countries

Absolute amounts and growth rates at constant exchange rates (2013)

Pharma: ASCO 2014 highlights



Immuno-oncology

- Anti-PDL1 data in new tumour type
- Immuno-oncology program update

Hematology

- Bcl2 inh*, Ph I in CLL (combo w/ Rituxan) and DLBCL
- Anti-79b ADC, PhII ROMULUS

Avastin

- H2H Avastin vs. cetuximab in mCRC (CALGB 80405 study)

Zelboraf+cobimetinib (MEK inh)


- PhIb BRIM7 data

Analyst meeting: Sunday, June 1 2014

* In collaboration with AbbVie

Pharma: Immunology growth franchise & pipeline

Immunology franchise sales




¹ CER=Constant Exchange Rates

Lebrikizumab in severe asthma

- Phase II: significant reduction in exacerbation rates
- Benefit in periostin high patients
- Phase III ongoing: filing 2016
- 2 doses tested in phase III

Pharma: 14 new entities in late-stage development



¹ Phase III decision pending

Pharma: 2014 key late-stage pipeline news I

Major readouts


Compound	Indication	Milestone
<i>bitopertin</i>	Schizophrenia	Ph III x
<i>cobimetinib (MEKi)</i>	Met. melanoma	Ph III (combo w Zelboraf)
<i>Kadcyla & Perjeta</i>	HER2+ mBC (1 Line)	Ph III MARIANNE
<i>onartuzumab (MetMAB)</i>	Lung cancer (2/3L)	Ph III (combo w Tarceva) x
<i>oral octreotide</i>	Acromegaly	Ph III Data available
<i>alectinib (ALKi)</i>	NSCLC	Ph II
<i>anti-HER3 EGFR DAF</i>	Head and neck, colorectal cancer	Ph II (MEHGAN, DARECK)
<i>anti-PDL1</i>	Solid tumours	Ph I/II Data available
<i>crenezumab</i>	Alzheimer's	Ph II Data available
<i>mGlu2/5</i>	Neuroscience	Ph II
<i>quilizumab (M1 prime)</i>	Asthma	Ph II (COSTA)

Pharma: 2014 key late-stage pipeline news II

Regulatory milestones

Compound	Indication	Milestone
<i>Actemra subcutaneous</i>	Rheumatoid arthritis	EU approval
<i>Avastin</i>	Glioblastoma	EU approval
<i>Avastin</i>	Cervical cancer	US, EU filing
<i>Avastin</i>	Pt-resistant ovarian cancer	EU approval
<i>MabThera subcutaneous</i>	NHL	EU approval ✓
<i>obinutuzumab (GA101)</i>	Front line CLL	EU approval
<i>Xolair</i>	Chronic idiopathic urticaria	US approval ✓

Diagnostics: Q1 2014 highlights




¹ Underlying growth of Molecular Diagnostics excluding Sequencing Solutions: +7%
CER=Constant Exchange Rates; EMEA=Europe, Middle East and Africa

Diagnostics: IQum acquisition

Entering Molecular Diagnostics (MDx) Point of Care

Liat™ Analyzer



Target market:

- ~CHF 350m, growing ~20%

Liat (laboratory in a tube) technology:

- Fast and simple with automated process performed in a test tube
- Brings laboratory PCR to the Point of Care
- Short turnaround time

Portfolio:

- Analyzer and Influenza A/B assay approved
- Strep A and Respiratory Syncytial Virus tests in clinical studies
- Planned expansion into MRSA and C-difficile

Group: 2014 outlook

Group sales growth¹

Low- to mid-single digit

Core EPS growth¹

Ahead of sales growth

Dividend outlook

Further increase dividend

¹At constant exchange rates

Roche in brief

Innovation & productivity

- **Focused innovation strategy**

- Personalized Healthcare through Pharma & Diagnostics
- Medically-differentiated products & services

- **Biotech-based businesses**

- Leader in Oncology, expanding in Immunology/Ophthalmology; exploring Neuroscience. Limited patent risk
- World's #1 in-vitro Diagnostics company

- **Strong financials**

- Increasing profitability through growth & productivity with constant focus on cash flow
- Attractive dividend



Doing now what patients need next